Startseite
Kongressberichte 2020
All-Virtual 62nd ASH Annual Meeting and Exposition
Oral Sessions
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond
Watch Session
647 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and OpticHagop M. Kantarjian, Michael W. Deininger, Elisabetta Abruzzese, et al.
648 Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)
according to ASH clinically relevant abstract
Monica Bocchia, Anna Sicuranza, Paola Pacelli, et al.
649 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study according to ASH clinically relevant abstract
Delphine Rea, Michael J. Mauro, Jorge E. Cortes, et al.
650 Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial according to ASH clinically relevant abstract
Jorge E. Cortes, Timothy P. Hughes, Michael J. Mauro, et al.
651 Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials according to ASH clinically relevant abstract
Qian Jiang, Xiaojun Huang, Zi Chen, et al.
Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, et al.